MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?

Merck (MRK) and Bristol Myers Squibb (BMY) are assessed for investment appeal, with both underperforming the large-cap pharma industry year-to-date. MRK's growth is driven by Keytruda's expanding indications, a robust pipeline, and a $3 billion cost-saving plan by 2027, though it faces Keytruda's 2028 patent cliff and declining Gardasil sales. BMY relies on its Growth Portfolio, including Opdivo, Reblozyl, and Camzyos, and targets $2 billion in annual cost savings by 2027, but navigates substantial revenue erosion from legacy drugs due to generic competition and maintains a high 73.8% debt-to-capital ratio. Despite BMY's lower forward P/E (7.02x vs. MRK's 8.24x) and higher dividend yield, MRK is deemed the smarter pick due to its portfolio diversity and pipeline strength.

Analysis

Both Merck (MRK) and Bristol Myers Squibb (BMY) are underperforming the large-cap pharmaceutical industry, with their shares declining 19.7% and 20.5% year-to-date, respectively, against a 1.6% industry gain. Despite this, both trade at a significant discount to the sector's 14.67x forward P/E ratio, with MRK at 8.24x and BMY at 7.02x. Merck's growth is sustained by its blockbuster drug Keytruda, which saw sales rise 7% in the first half of 2025 and recently received approval for a subcutaneous formulation, potentially extending its franchise value. This is supplemented by a robust pipeline, nearly tripled since 2021 through M&A, and a $3 billion cost-saving plan. However, MRK faces a major headwind with Keytruda's patent expiry in 2028 and currently declining sales for its second-largest product, Gardasil. In contrast, BMY is navigating a challenging transition as its 'Growth Portfolio' (Opdivo, Reblozyl) attempts to offset steep revenue declines from legacy drugs facing generic competition, reflected in a consensus sales forecast decline of 2.06% for 2025. While BMY's new drug uptake is positive and it has a $2 billion cost-saving program, its balance sheet is highly leveraged with a debt-to-capital ratio of 73.8%, significantly higher than MRK's 0.41.

Key Decisions for Investors

• Investors may find Merck a relatively more stable investment due to its diverse portfolio, positive 2025 sales and EPS growth forecasts of 1.21% and 16.73% respectively, and a stronger balance sheet, but must remain focused on the execution of its pipeline to mitigate the 2028 Keytruda patent cliff.
• Bristol Myers Squibb presents a higher-risk, higher-reward value proposition; its lower forward P/E of 7.02x and superior dividend yield of 5.61% may attract income-oriented investors, but this must be weighed against its high leverage and ongoing revenue erosion from legacy products.
• Given both stocks' significant underperformance, positions in either name should be contingent on a belief that the market is overly discounting their ability to navigate patent cliffs through pipeline development and cost-cutting initiatives.
• Key performance indicators to monitor are the sales growth of MRK's new products like Winrevair and stabilization of Gardasil sales, versus the net revenue impact of BMY's Growth Portfolio's performance against the decline of its legacy drugs.